We have investigated the effect of a 6-day infusion of recombinant human (rh) IGF-I (0.3-1.0 mg/day) or rhGH (200 mU/day) into normal and hypophysectomized rats on the ventricular expression of myofibrillar genes (a-and b-myosin heavy chain (MHC), skeletal and cardiac a-actin) and of atrial natriuretic factor (ANF). In normal rats, b-MHC was not detectable either before or after IGF-I or GH, but a-MHC mRNA increased significantly (twofold) with GH (not statistically significant for IGF-I). In contrast to normal rats, hypophysectomized rats did not express a-MHC either before or after IGF-I or GH, but b-MHC was strongly expressed and significantly stimulated (1.8-fold) by IGF-I (not statistically significantly with GH). Skeletal a-actin expression remained unchanged during IGF-I or GH treatment of normal rats, but was enhanced by both IGF-I and GH (2.5-and 2.8-fold respectively) in hypophysectomized rats. Expression of cardiac a-actin in normal and hypophysectomized rats was not altered by either treatment. IGF-I and GH decreased ventricular expression of ANF in normal rats by 63% and 45% respectively, but did not influence ANF expression in hypophysectomized rats. Our results show that IGF-I and GH (possibly via IGF-I) stimulate expression of myofibrillar genes and modulate ANF mRNA concentrations in rat heart ventricles in vivo, depending on the hormonal status of the animals. However, neither IGF-I nor GH caused a shift from the b-to the a-MHC isoform in hypophysectomized rats.
Introduction
During overload-induced cardiac hypertrophy, ventricular heart cells re-express foetal gene products such as skeletal a-actin, smooth muscle a-actin and atrial natriuretic factor (ANF) and switch from the a-to the b-myosin heavy chain (MHC) as the main isoform (1) (2) (3) (4) (5) . Several pieces of evidence point to a specific role of insulin-like growth factor-I (IGF-I) and growth hormone (GH) in cardiomyocyte plasticity. IGF-I preferentially stimulates heart, and to a lesser extent skeletal, muscle growth of hypophysectomized rats, whereas both heart and skeletal muscle growth are stimulated by GH (6) . GH and thyroid hormone promote IGF-I gene expression in whole heart tissue in vivo (7, 8) . IGF-I, but not GH, increases b-MHC (9) and skeletal a-actin (10) of cultured neonatal cardiomyocytes, and enhances myofibril development and suppresses smooth muscle a-actin in long-term cultures of adult rat cardiomyocytes (11) . The in vivo effect of IGF-I on heartspecific gene expression has not been investigated.
Changes in ventricular IGF-I expression have been shown to occur during cardiac hypertrophy (12) (13) (14) . Furthermore, administration of IGF-I has been shown to improve doxorubicin-induced cardiomyopathy (15) and to enhance left ventricular function in normal rats (16) and in rats developing cardiac failure (17) . Recently, Fazio et al. (18) reported a beneficial effect of GH in the treatment of dilated cardiomyopathy in man.
We studied the effects of IGF-I and GH on hearts of normal and hypophysectomized rats in order to address the following questions : (i) Do IGF-I and GH affect aand b-MHC, a-actin isoforms and ANF in vivo? (ii) Does IGF-I mimic GH effects on the heart? (iii) Do the effects of GH and IGF-I on hearts of normal rats differ from those in hypophysectomized rats? As hypophysectomized rats are deficient not only in GH and IGF-I, but also in thyroid and steroid hormones, differences between the patterns of expression of cardiac genes of GH-or IGF-Itreated normal and hypophysectomized rats may reflect the impact of these hormones on GH/IGF-I action on the heart. Ciba-Geigy AG, Basel, Switzerland). Animals that gained less than 2 g/week over 3 weeks were selected. Alzet miniosmotic pumps (model 2001, Alza Corp., Palo Alto, CA, USA) were filled with recombinant human (rh)IGF-I (Ciba-Geigy AG) dissolved in 0.1 mol/l acetic acid, rhGH (Nordisk, Gentofte, Denmark) dissolved in H 2 O, or solvent (0.1 mol/l acetic acid). The minipumps were implanted in the abdominal subcutis under ether anaesthesia.
Rats were allocated to three groups of seven hypophysectomized animals to receive 6-day infusions of rhIGF-I (300 mg/day), rhGH (200 mU/day), or solvent. Three additional groups of six age-matched normal animals received the same treatment, except that the dose of rhIGF-I was 1000 mg/day. Food and water intake and body weight were measured daily.
After 6 days of infusion, rats were anaesthetized with Innovar Vet (Pitman Moore, Washington Crossing, NJ, USA; 0.2 ml/100 g body weight) and bled by aortic puncture. Hearts were rapidly excised, weighed and immediately frozen in liquid nitrogen. They were stored at ¹80 ЊC until required for extraction of RNA.
The animal experiments were approved by the Veterinary Council of the Kanton of Zü rich, whose guidelines for the care and use of animals were followed.
RNA extraction and Northern blotting
Ventricular tissue was dissected from blood vessels and atria, and total RNA was extracted according to standard procedures (19) . Frozen tissue (0.5-0.8 g) was homogenized in 4 mol/l guanidinium isothiocyanate, pH 7.0, containing 5 mmol/l sodium citrate, 0.1 mol/l b-mercaptoethanol and 0.5% sarcosine, and RNA was extracted through a caesium chloride gradient (19) . RNA samples were then dissolved in diethylpyrocarbonate-treated H 2 O and concentrations determined spectrophotometrically at 260 nm.
Denatured RNA (20 mg per lane) was electrophoresed on a 1% agarose gel containing 2 mol/l formaldehyde, transferred to a nylon membrane (Hybond-N, Amersham International, Bucks, UK) and the RNA fixed by UV crosslinking. The filters were prehybridized at 37 ЊC (for the a-MHC probe) or at 42 ЊC (for the other probes) for 2 h in a solution containing 25% (a-MHC hybridization) or 50% formamide, 5 × Denhardt's (0.02% (w/v) Ficoll, 0.02% (w/v) polyvinyl pyrrolidone), 5 × SSPE (20 × SSPE ¼ 3.6 mol/l NaCl, 0.2 mol/l sodium phosphate, 0.02 mol/ l EDTA pH 7.7), 0.2% SDS and 100 mg/ml of heatdenatured salmon sperm DNA. The following cDNA probes were used for hybridization: rat skeletal a-actin and cardiac a-actin cDNA corresponding to the 3 0 -untranslated regions (kindly provided by Dr P Gunning, Cell Biology Unit, Children's Medical Research Institute, Wentworthville, Australia), mouse ANF cDNA (kindly provided by Dr K R Chien, Center of Molecular Biology, La Jolla, CA, USA). These cDNA probes were labelled by random primer extension using a commercial kit (Boehringer Mannheim, Germany) and [a-
32 P]deoxycytidine 5 0 -triphosphate (ϳ3000 Ci/mmol, Amersham). The a-and b-MHC mRNAs were identified using specific oligonucleotides (synthesized by Microsynth, Windisch, Switzerland) corresponding to 20 mers from the 3 0 -untranslated regions of the MHC mRNAs (20) . Oligonucleotide probes were labeled at the 5 0 end using a commercial kit (Boehringer Mannheim) and [g- 
IGF-I determination
Serum IGF-I (endogenous or infused) was separated from binding proteins by chromatography of 0.1 ml serum (adjusted to 0.25 ml with PBS-0.2% human serum albumin (HSA)) on Sep-Pak C18 cartridges (Waters, Millipore, Milford, MA, USA) according to the protocol supplied by Immunonuclear (Stillwater, MN, USA). After reconstitution with 1 ml PBS-0.2% HSA, pH 7.4, samples were assayed at three different dilutions. Immunoreactive rat IGF-I was determined by RIA using a rabbit antihuman IGF-I antiserum at a final dilution of 1 : 20 000 (21) and rat IGF-I as a standard (gift from Dr M Kobayashi, Fujisawa, Japan). Infused rhIGF-I was measured with a rabbit antihuman IGF-I antiserum that does not crossreact significantly with rat IGF-I (22), and rhIGF-I (Ciba-Geigy AG) as a standard.
125 I-Labelled rhIGF-I (ϳ350 Ci/g; Anawa, Wangen, Switzerland) was used as a tracer.
In the rat IGF-I RIA, rhIGF-I crossreacts significantly (five-to tenfold) more than rat IGF-I, but not in a parallel fashion, therefore this assay cannot be used to measure total (human þ rat) IGF-I concentrations in the rhIGF-I-infused animals.
Statistical analysis
The results for different groups of animals are expressed as means Ϯ S.E. Student's t-test was used for statistical analysis of serum and growth parameters (Table 1) , and the Wilcoxon test for statistical analysis of normalized mRNA concentrations (Fig. 1a-c) .
Results

Serum and growth parameters
Endogenous IGF-I serum concentrations in normal control animals were 1665 Ϯ 90 ng/ml. This value did not increase significantly after rhGH treatment (1760 Ϯ 80 ng/ml), as has been observed previously (23) . Similarly, body weight gain in normals after rhGH was not significantly different from that in salinetreated controls ( Table 1 ). The serum concentration of exogenous rhIGF-I after rhIGF-I treatment of normal rats was 1420 Ϯ 44 ng/ml. This value does not reflect the total concentration of circulating IGF-I (endogenous rat IGF-I þ exogenous rhIGF-I), because rat IGF-I does not crossreact in our RIA. However, infusion experiments with the same dose of rhIGF-II in normal rats have shown that endogenous rat IGF-I is suppressed by approximately 50% (J Zapf, unpublished observations), and we therefore assumed that infusion of rhIGF-I 1 mg/ day caused a comparable suppression of endogenous rat IGF-I. Thus the total circulating IGF-I concentration in the rhIGF-I-infused normal animals can be estimated to amount to ϳ2300 ng/ml (Table 1) .
After hypophysectomy, endogenous IGF-I concentrations decreased to 54 Ϯ 3 ng/ml; they increased to 775 Ϯ 32 ng/ml after rhGH treatment. Exogenous rhIGF-I concentrations reached 338 Ϯ 225 ng/ml after rhIGF-I treatment. In hypophysectomized rats infused with rhIGF-II 0.4 or 1 mg/day, the low endogenous IGF-I concentrations are not further suppressed (J Zapf, unpublished observations). By analogy, this should also be true during rhIGF-I infusion. Therefore, total circulating IGF-I in rhIGF-Iinfused hypophysectomized animals can be calculated by adding endogenous IGF-I concentrations of untreated controls to exogenous rhIGF-I values. Total IGF-I in the rhIGF-infused hypophysectomized group would thus be around 390 ng/ml (Table 1 ). This is still only 50% of the endogenous IGF-I value in the GHinfused group. However, the two values cannot readily be compared, as the turnover of infused rhIGF-I is increased in hypophysectomized animals because of the lack of the 150 kDa IGF binding protein (IGFBP) complex (21) , which is induced by GH treatment (21) and which prolongs the half-life of circulating IGF. The difference between the exogenous rhIGF-I serum concentrations of rhIGF-I-infused normal and hypophysectomized rats is also explained by the lack of the 150 kDa IGFBP complex and the enhanced turnover of infused rhIGF-I in the hypophysectomized animals (24) .
Serum concentrations of free thyroxine decreased from 58.1 Ϯ 4.78 pmol/l in normal rats to 4.65Ϯ 0.15 pmol/l after hypophysectomy, and serum testosterone concentrations decreased from 11.6Ϯ 1.45 nmol/l to values less than 0.4 nmol/l. None of these values was significantly influenced by IGF-I or GH treatment (not shown). (total ϳ390**) (n ¼ 7) Hypox vs rhGH P < 0:0001 P < 0:01 P < 0:01 P < 0:03 P < 0:05 Hypox vs rhIGF-I P < 0:0001 P < 0:01 P < 0:02 n.s. P < 0:05 rhGH vs rhIGF-I P < 0:001 P < 0:05 n.s. P < 0:01 n.s.
* Exogenous þ 1=2 endogenous ϳ2250 ng/ml (see explanation in Results). ** Exogenous þ endogenous ϳ390 ng/ml (see explanation in Results).
Figure 1
Effects of rhGH and rhIGF-I in ventricular heart tissue of normal and hypophysectomized rats infused with saline (control), rhGH or rhIGF-I. Total RNA extracted from heart ventricles was electrophoresed, transferred to a nylon membrane and hybridized as described in Materials and methods. Quantification of the hybridization signals was performed by scanning densitometry. Data were corrected for the corresponding 18S ribosomal RNA values. The values of the vehicle-treated controls were taken as 100%. n ¼ 6 ¹ 7 for each group of hypophysectomized rats; n ¼ 6 for each group of normal rats. *P < 0:05 between control and GH or IGF-I (Wilcoxon test). As observed previously (6), rhIGF-I (300 mg/day) preferentially stimulated heart growth and not soleus muscle of hypophysectomized rats (Table 1) , whereas both heart and soleus muscle growth were stimulated by rhGH (200 mU/day) ( Table 1) . In normal rats, IGF-I 1 mg/day or GH (200 mU/day) did not significantly stimulate heart or skeletal (soleus) muscle weight ( Table 1) .
Effects of IGF-I and GH on a-and b-MHC in normal and hypophysectomized rats
In normal rats, b-MHC expression was not detectable; a-MHC expression was stimulated twofold by GH and IGF-I, but stimulation by IGF-I did not reach statistical significance. Hypophysectomy caused a complete shift from the a-to the b-MHC isoform (Figs 1a, 2) . Neither GH nor IGF-I was able to reverse this shift. b-MHC mRNA concentrations in hypophysectomized rats were stimulated 1.8-fold by IGF-I, but stimulation of b-MHC by GH did not reach statistical significance.
Effects of IGF-I and GH on skeletal and cardiac a-actin isoforms in normal and hypophysectomized rats
GH and IGF-I had no significant effect on expression of skeletal a-actin in normal rats (Figs 1b, 2) , and neither did hypophysectomy change skeletal a-actin expression (not shown). In contrast, however, IGF-I and GH significantly stimulated the skeletal a-actin message in hypophysectomized rats (2.5-and 2.8-fold respectively) (Figs 1b, 2) . Cardiac a-actin mRNA concentrations remained unchanged in normal and hypophysectomized rats under all experimental conditions described above.
Effect of IGF-I and GH on ANF expression in normal and hypophysectomized rats
ANF expression was not significantly different in normal and hypophysectomized rats (not shown). However, both IGF-I and GH suppressed expression of ANF by 63% and 45% respectively in normal rats (Figs 1c, 2) . Treatment of hypophysectomized rats with GH or IGF-I did not produce significant change in ANF expression (Figs 1c, 2) .
Discussion
This study has shown that IGF-I administered in vivo enhances the expression of myofibrillar genes and modulates the expression of ANF in rats, depending on their endocrine status. These effects are similar to those observed with infusion of GH, but they differ in normal and hypophysectomized animals. Thus GH and IGF-I stimulated a-MHC expression (not statistically significant for IGF-I) in normal but not in hypophysectomized rats. Conversely, IGF-I enhanced b-MHC expression in hypophysectomized rats (stimulation by GH did not reach statistical significance), but not in normal rats. IGF-I, in common with GH, decreased ANF expression in normal rats without causing any changes in skeletal or cardiac a-actin mRNA concentrations. However, both IGF-I and GH significantly increased expression of skeletal a-actin in hypophysectomized rats, without changes in cardiac a-actin mRNA or ANF expression. The above differences between normal and hypophysectomized rats may be mainly attributable to thyroid hormone deficiency in hypophysectomized rats, which has been shown to be responsible for a shift from a-to b-MHC expression (25) .
Our data also demonstrate that IGF-I per se is not able to cause a shift between a-and b-MHC, but rather, it stimulates expression of the MHC isoform that is already present. On the other hand, the suppressive effect of IGF-I on ventricular expression of ANF in normal rats and its stimulatory (although not statistically significant) effect on a-MHC expression in these animals suggest that IGF-I favours the expression of an adult cardiac protein pattern in normal, endocrine-competent animals. ANF mRNA is expressed not only in the atria of the normal adult rat heart, but also, although in lower concentrations, throughout the cardiac ventricle from apex to base (26) . The suppression of ventricular ANF by IGF-I in our normal rats is consistent with in vitro findings in cultured adult rat cardiomyocytes (27) . ANF expression is upregulated after induction of overload and decreases later (28) . Possibly, this decrease is induced by an increase in local IGF-I expression during cardiac hypertrophy (12) (13) (14) and reflects a stage of hypertrophy at which the diuretic effect of ANF is no longer required to compensate overload. The concomitant increase in contractile protein mRNA by IGF-I and in contractile protein as demonstrated in cardiomyocytes in vitro (11) would favour cardiac recompensation, so that the decrease in ANF, at this particular moment, appears plausible. Furthermore, the finding that IGF-I stimulates b-MHC in hypophysectomized rats in vivo is in agreement with in vitro findings in cultured neonatal heart cells (9) . In cardiomyocyte cultures, IGF-I stimulates b-MHC, which is expressed by these cells, but it is unable to do so in the presence of thyroid hormones that suppress this MHC isoform.
Some of our results with GH are at variance with other reports. For example, GH-secreting tumours implanted into normal rats (29) (30) (31) or long-term subcutaneous administration of GH (32) caused a shift from the previously exclusive a-MHC to expression of both a-and b-MHC. These differences may be explained as follows. First, the latter results were obtained after 5-18 weeks of GH hypersecretion as a result of tumour transplantation or after 6 months of subcutaneous GH injections, whereas treatment in our study lasted for 6 days only. Chronic GH hypersecretion or treatment is associated with an increase in plasma volume and heart load (33) . Therefore, the shift of MHC-isoforms in these long-term studies may primarily reflect volume overload rather than a 'direct' GH effect. In this context, it is noteworthy that Florini & Ewton (9) did not observe a change in myosin ATPases during short-term (2 weeks) subcutaneous GH treatment of normal rats, suggesting that a switch of MHC isoforms had not by then occurred. Secondly, the observation by Timsit et al. (30) that longterm GH hypersecretion by transplanted tumours caused an eightfold decrease in tri-iodothyronine concentrations suggests that this may have contributed to the switch from the a-to the b-MHC isoform (25) . Thirdly, the changes in a-and b-MHC reported during long-term GH action were relatively modest compared with the magnitude of cardiac enlargement (29, 30, 32) . Therefore, because of continuing cardiac overload, a certain amount of b-MHC may be expected to be expressed in parallel with further a-MHC stimulation after prolonged administration of GH.
In view of the effects of GH on the expression of cardiac protein, and earlier findings showing that GH treatment of rats increases heart weight (6, 29, 30; Table 1 ) and that it stimulates IGF-I gene expression in whole heart tissue (7), it may appear surprising that we (11) and others (10) were unable to observe any effects of GH on cultured adult rat cardiomyocytes. One explanation for this discrepancy may be that GH in vivo does not act directly on cardiomyocytes, but rather it acts on adjacent interstitial cells of the heart to produce IGF-I, which would then act on the cardiomyocytes in a paracrine fashion. The fact that the effects of GH observed in this study were mimicked by IGF-I is in line with this explanation. Nevertheless, these results do not exclude direct (IGF-I-independent) effects of GH on the expression of cardiac protein.
In conclusion, our study shows that IGF-I and GH (possibly via IGF-I) can increase MHC isoforms and skeletal a-actin, and decrease ANF expression, depending on the physiological or pathophysiological state of the animal. The stimulation of contractile protein mRNAs and the regulation of ANF expression suggest a modulatory role of IGF-I (and GH) in cardiac protein expression and possibly in cardiomyocyte plasticity, in particular during cardiac hypertrophy. 
